tachycardia

(redirected from Ventricular tachycardia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

tachycardia:

see arrhythmiaarrhythmia
, disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of additional symptoms.
..... Click the link for more information.
.

Tachycardia

 

an increase in the frequency of cardiac contractions. In some cases it is not perceived subjectively; in others, it is accompanied by palpitations.

A distinction is made between sinus tachycardia, or the accelerated generation of impulses in the sinus node of the heart, and paroxysmal tachycardia. Sinus tachycardia, manifested by contractions generally ranging between 90 and 120 per minute, may be caused by such physiological factors as increased environmental temperature, physical and mental tension, or the ingestion of food. Sinus tachycardia may also be caused by such pathological states as fever, anemia, diffuse toxic goiter, heart failure, and neurasthenia. Nervous and humoral influences on the heart, such as adrenalin and thyroxine, are important contributing factors in the genesis of sinus tachycardia. The accelerated rhythm of cardiac contractions may have an unfavorable effect on metabolism in the myocardium and on blood circulation. When tachycardia is a symptom of disease, the underlying disease is treated.

tachycardia

[¦tak·ə¦kärd·ē·ə]
(medicine)
Excessive rapidity of the heart's action.
References in periodicals archive ?
In this study, we attempted to further explore the relationship of depolarization to orthogonal components of repolarization in patients with previous MI, with and without recent history of sustained ventricular tachycardia on Holter recordings.
During 52 months of follow-up, major arrhythmic events defined as sustained ventricular tachycardia, fibrillation or SCD occurred in 46 of 343 patients (13%).
Localization of the site of origin of postinfarction ventricular tachycardia by endocardial pace mapping.
This study provides more evidence than we have for any other antiarrhythmic in the ventricular fibrillation/pulseless ventricular tachycardia ACLS algorithm, other than magnesium for known hypomagnesemia.
The patients had not responded to standard treatments and collectively experienced more than 6,500 episodes of ventricular tachycardia in the three months before they were treated with radiation therapy.
One of these patterns in conjunction with the presence one of the following criteria: a history of documented ventricular fibrillation, a history of documented ventricular tachycardia, family history of sudden cardiac death (SCD) before the age of 45, a family history of type 1 Brugada pattern ECG changes, nocturnal agonal respiration during sleep, unexplained syncope suggestive of tachyarrhythmia, or inducible ventricular tachycardia/ventricular fibrillation during electrophysiological study.
Caption: FIGURE 2: Modified lead II telemetry strip, recorded 4 hours after the ECG in Figure 1 showed the end of a 30- second run of monomorphic wide-QRS tachycardia (122 beats/min) with a different morphology and thought to be ventricular tachycardia.
Additionally, the report provides an overview of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects.
The workshop aimed to train medical staff on the best ways to conduct catheter for ventricular tachycardia by the three-dimensions imaging used for the first time in the Sultanate, acquaint them with the latest treatment and diagnostic methods in the field of cardiac catheterization, as well as sharing experiences and views on the basics of cardiac catheterization.
The development of monomorphic ventricular tachycardia (VT) and/or ventricular premature depolarizations (VPDs) beyond the acute phase following blunt chest trauma is more commonly associated with right or left ventricular structural abnormalities but with little understanding of the underlying mechanisms or recommended therapies.
Audentes said it plans to rapidly advance Cardiogen's lead program for the CASQ2subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT) into clinical development.

Full browser ?